South Africa has named three local firms that could produce the six-monthly HIV-prevention injection LEN, sparking a debate over cost, timing and the country’s broader drug-making ambitions.
The long-acting jab blocks HIV infection for half a year, offering an alternative to daily pills and positioning LEN as a potential game-changer in prevention strategies.
Licensing and technology transfer
In July, Deputy Health Minister Joe Phaahla announced that a committee convened by the South African National AIDS Council submitted the shortlist to Gilead Sciences for assessment and possible voluntary licensing.
Existing generic licences granted to manufacturers in Egypt, India and Pakistan require full-process production, including the active pharmaceutical ingredient (API), whereas a South African licence could allow import of the API and focus on downstream steps.
Local producers would likely begin with assembling the sterile injectable, packaging and quality-control, tasks that can be set up more quickly than building an API plant.
“Local manufacturing” in this context means producing parts of the drug within the country, not achieving complete self-sufficiency in the supply chain.
Demand, pricing and market size
A key risk is that a manufacturer invests in capacity only to face a market too small to sustain affordable pricing, especially if production is limited to South Africa.
Supplying a regional bloc could improve economies of scale; pooled orders from neighboring countries would lower the per-dose cost.
Guaranteeing demand is essential, and organisations such as Unitaid have signalled willingness to back purchases that secure a stable market for locally made LEN.
Without such assurances, a local licence might remain symbolic rather than delivering broader access.
Related Post: South Africa tracks vaccine follow up doses
While generic versions from existing licence holders are expected to reach the market by 2027, the timing of those approvals will shape the role of any South African product.
Importing affordable generics now could protect at-risk populations, even as technology transfer and facility upgrades proceed in parallel.
The committee’s review of the shortlist is slated to take between three and six months, after which Gilead will decide on the scope of the voluntary licence.
Steps toward a functional production line
Achieving a workable supply chain will require a formal licence that outlines the scope of local work and the responsibilities of the developer. The licence must grant access to the formulation data and allow import of the active ingredient, while specifying quality-control standards.
Manufacturers will need to modify existing sterile-injection facilities to accommodate the specific fill-finish process for the jab. Validation runs will demonstrate that the product meets stability criteria over the six-month period.
Once a pilot batch passes internal testing, a regulatory dossier will be compiled for submission to the national medicines authority. The authority will conduct inspections of the production site and review the data before issuing a marketing authorisation.
Training programmes will be established to up-skill staff in aseptic techniques and analytical testing. Ongoing monitoring will include batch-release testing and post-marketing surveillance to ensure continued safety.
Financing, procurement and regional collaboration
Predictable purchasing commitments are essential for manufacturers to justify the capital outlay needed for line upgrades. Government agencies can outline expected volumes in multi-year procurement plans, giving producers a clearer revenue outlook.
In conclusion, the success of local LEN production in South Africa depends on several factors, including guaranteed demand, pricing, and market size, as well as the ability to work through the complexities of licensing, technology transfer, and regulatory approval, ultimately determining the feasibility of making this key HIV prevention injection on home soil.